Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Where
Shenzhen
Age
18 years to 75 years
People
60
Run by
Beijing Biotech
See details and how to joinNCT07641023
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Where
Guangzhou
Age
18 years and over
People
178
Run by
Shenzhen Ionova Life Sciences Co., Ltd.
See details and how to joinNCT07610798
Phase 1Taking people
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
150
Run by
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
See details and how to joinNCT07638891
Phase 2Taking people
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
Where
Guangzhou
Age
18 years and over
People
32
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07637448
Phase 2Taking people
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Where
Guangzhou
Age
18 years and over
People
30
Run by
Guangzhou Institute of Respiratory Disease
See details and how to joinNCT06497530
Phase 2Not yet taking people in China
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Where
Beijing, Harbin
Age
18 years to 80 years
People
227
Run by
GV20 Therapeutics
See details and how to joinNCT07623642
Phase 2Not yet taking people in China
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
Where
Guangzhou
Age
18 years to 75 years
People
30
Run by
Sun Yat-sen University
See details and how to joinNCT07630077
Phase 2Taking people
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Where
Shanghai
Age
18 years to 75 years
People
60
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07269782
Phase 1Taking people
Safety and Preliminary Activity of BI115 in Advanced SCLC
Where
Chongqing
Age
18 years to 75 years
People
150
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07559019
No phaseTaking people
Association Between Screening Behaviors and Lung Cancer Spectrum
Where
Shanghai
People
5,390
Run by
Fudan University
See details and how to joinNCT07626177
No phaseTaking people
Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
Where
Guangzhou
Age
18 years and over
People
300
Run by
Wen-zhao ZHONG
See details and how to joinNCT07626736
Phase 2Not yet taking people in China
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
Where
Hefei
Age
18 years to 75 years
People
39
Run by
Anhui Provincial Cancer Hospital
See details and how to joinNCT07627321
No phaseTaking people
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Where
Beijing
People
80
Run by
Peking University People's Hospital
See details and how to joinNCT07359040
Phase 1Not yet taking people in China
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
Where
Hangzhou
Age
18 years and over
People
198
Run by
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT07624214
Phase 1Taking people
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Where
Shanghai
Age
18 years and over
People
502
Run by
Hansoh BioMedical R&D Company
See details and how to joinNCT06936735
Phase 2/3Taking people
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Where
Beijing
Age
18 years and over
People
706
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07459751
Phase 2Taking people
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
Where
Hangzhou
Age
18 years and over
People
120
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07617246
Phase 3Not yet taking people in China
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
Where
Guangzhou
Age
18 years to 75 years
People
358
Run by
Wen-zhao ZHONG
See details and how to joinNCT07617389
Phase 2Not yet taking people in China
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
Where
Beijing
Age
18 years to 75 years
People
60
Run by
zhang yi
See details and how to joinNCT07618793
Phase 2/3Taking people
Trop2-targeted immunoPET Imaging of Solid Tumors
Where
Shanghai
Age
18 years to 75 years
People
400
Run by
RenJi Hospital
See details and how to joinNCT06851663
No phaseTaking people
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
Where
Guangzhou
Age
18 years to 75 years
People
585
Run by
Wen-zhao ZHONG
See details and how to joinNCT07612722
No phaseTaking people
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Where
Wuhan
Age
18 years to 65 years
People
100
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06843629
No phaseTaking people
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
Where
Guangzhou
Age
18 years to 100 years
People
10
Run by
Guangzhou Institute of Respiratory Disease
See details and how to joinNCT07610616
Phase 1/2Taking people
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Daping, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing, Shanghai, Shatin, Shenyang, Shenzhen, Taiyuan, Weifang, Wuhan, Xiamen, Xi'an, Xuzhou, Zhengzhou
Age
12 years and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00
Phase 2Not yet taking people in China
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
Where
Wuhan
Age
18 years and over
People
90
Run by
Sinocelltech Ltd.
See details and how to joinNCT07609251